Company intelligence / Profile preview

Amneal Pharmaceuticals, Inc.

Bridgewater, New Jersey, United Statesamneal.com ↗
Ownership
Public · AMRX
Employees
~8000
Development stage
Other
01

Overview

Amneal has a diverse portfolio of over 280 generic and specialty pharmaceuticals. The company has 3 FDA-approved biosimilars in the market with more in development. They focus on complex generics, specialty products, oncology biosimilars, and institutional injectables.

Therapeutic areas
Neurology
Modalities
Generic pharmaceuticalsSpecialty pharmaceuticalsBiosimilarsInjectables
Industry
Biotech
02

Drug pipeline

23 assets

dexamfetamine sulfate

Approved

22 more assets in the full pipeline.

03

Financials

Market cap
$6.8B
Total revenue
$3B
Enterprise value
$9.9B

Beyond the preview

Go deeper on Amneal Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amneal Pharmaceuticals, Inc..

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call